🇺🇸 FDA

Company profile · Sponsor

Ascendis

Ascendis Pharma Bone Diseases A/S

E0B1B8E · EMA pharma EU
Pipeline
2
Drugs
0
Patents
0

Quick answer

Ascendis (E0B1B8E) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E0B1B8E
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (2)

Search pipeline →

  1. Yorvipath 420 micrograms/1.4 mL solution for injection in pre‑filled pen, Yorvipath 168 micrograms/0.56 mL solution for injection in pre-filled pen, Yorvipath 294 micrograms/0.98 mL solution for injection in pre‑filled pen

    Ascendis

    Chronic hypoparathyroidism

    phase 3 small molecule active

    1 trial

  2. TransCon PTH

    Ascendis

    Hypoparathyroidism (HP) in Adults

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Ascendis?

Ascendis (E0B1B8E) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Ascendis sponsor?

We track 2 ClinicalTrials.gov-linked programs for Ascendis, including Yorvipath 420 micrograms/1.4 mL solution for injection in pre‑filled pen, Yorvipath 168 micrograms/0.56 mL solution for injection in pre-filled pen, Yorvipath 294 micrograms/0.98 mL solution for injection in pre‑filled pen and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Ascendis company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.